Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $76.7 million.

  • Viking Therapeutics' Total Liabilities rose 17339.09% to $76.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.7 million, marking a year-over-year increase of 17339.09%. This contributed to the annual value of $76.7 million for FY2025, which is 17339.09% up from last year.
  • Viking Therapeutics' Total Liabilities amounted to $76.7 million in Q4 2025, which was up 17339.09% from $26.4 million recorded in Q3 2025.
  • Over the past 5 years, Viking Therapeutics' Total Liabilities peaked at $76.7 million during Q4 2025, and registered a low of $8.8 million during Q4 2021.
  • Its 5-year average for Total Liabilities is $22.4 million, with a median of $18.5 million in 2023.
  • Examining YoY changes over the last 5 years, Viking Therapeutics' Total Liabilities showed a top increase of 17339.09% in 2025 and a maximum decrease of 4029.92% in 2025.
  • Over the past 5 years, Viking Therapeutics' Total Liabilities (Quarter) stood at $8.8 million in 2021, then surged by 164.38% to $23.2 million in 2022, then dropped by 13.51% to $20.1 million in 2023, then skyrocketed by 39.72% to $28.0 million in 2024, then soared by 173.39% to $76.7 million in 2025.
  • Its Total Liabilities was $76.7 million in Q4 2025, compared to $26.4 million in Q3 2025 and $32.4 million in Q2 2025.